A Study of TG103 Injection in Overweight or Obesity
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II
study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of
two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight
or obesity, to support dose selection for further development.